CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade

• Glavni autori: Aixian Zheng (Autor), Yanlin Du (Autor), Yiru Wang (Autor), Youshi Zheng (Autor), Zhaoyu Ning (Autor), Ming Wu (Autor), Cuilin Zhang (Autor), Da Zhang (Autor), Jingfeng Liu (Autor), Xiaolong Liu (Autor)
• Format: Knjiga
• Izdano: Elsevier, 2022-03-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

It is well established that natural killer (NK) cells can be used as an alternative candidate of T cells for adoptive cell therapy (ACT) due to its high killing capacity, off-the-shelf utility, and low toxicity. Though NK cells provide rapid and potent immune effects, they still suffer from insuffic...